485 related articles for article (PubMed ID: 26810718)
1. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
Ayzenberg I; Schöllhammer J; Hoepner R; Hellwig K; Ringelstein M; Aktas O; Kümpfel T; Krumbholz M; Trebst C; Paul F; Pache F; Obermann M; Zeltner L; Schwab M; Berthele A; Jarius S; Kleiter I;
J Neurol; 2016 Mar; 263(3):575-82. PubMed ID: 26810718
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
Stellmann JP; Krumbholz M; Friede T; Gahlen A; Borisow N; Fischer K; Hellwig K; Pache F; Ruprecht K; Havla J; Kümpfel T; Aktas O; Hartung HP; Ringelstein M; Geis C; Kleinschnitz C; Berthele A; Hemmer B; Angstwurm K; Young KL; Schuster S; Stangel M; Lauda F; Tumani H; Mayer C; Zeltner L; Ziemann U; Linker RA; Schwab M; Marziniak M; Then Bergh F; Hofstadt-van Oy U; Neuhaus O; Zettl U; Faiss J; Wildemann B; Paul F; Jarius S; Trebst C; Kleiter I;
J Neurol Neurosurg Psychiatry; 2017 Aug; 88(8):639-647. PubMed ID: 28572277
[TBL] [Abstract][Full Text] [Related]
3. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
Fragomeni MO; Bichuetti DB; Oliveira EML
Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
[TBL] [Abstract][Full Text] [Related]
4. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
Viswanathan S; Wong AH; Quek AM; Yuki N
J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J
Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
[TBL] [Abstract][Full Text] [Related]
10. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
Kitley J; Elsone L; George J; Waters P; Woodhall M; Vincent A; Jacob A; Leite MI; Palace J
J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):918-21. PubMed ID: 23467418
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
[TBL] [Abstract][Full Text] [Related]
13. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
[TBL] [Abstract][Full Text] [Related]
15. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
[TBL] [Abstract][Full Text] [Related]
16. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M
Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder.
Yoshii F; Moriya Y; Ohnuki T; Ryo M; Takahashi W
Mult Scler Relat Disord; 2016 May; 7():53-7. PubMed ID: 27237757
[TBL] [Abstract][Full Text] [Related]
18. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
[TBL] [Abstract][Full Text] [Related]
19. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.
Palace J; Lin DY; Zeng D; Majed M; Elsone L; Hamid S; Messina S; Misu T; Sagen J; Whittam D; Takai Y; Leite MI; Weinshenker B; Cabre P; Jacob A; Nakashima I; Fujihara K; Pittock SJ
Brain; 2019 May; 142(5):1310-1323. PubMed ID: 30938427
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Yaguchi H; Sakushima K; Takahashi I; Nishimura H; Yashima-Yamada M; Nakamura M; Tsuzaka K; Maruo Y; Takahashi T; Yabe I; Sasaki H
Intern Med; 2013; 52(9):969-72. PubMed ID: 23648715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
